The new pathology facility will provide biopharmaceutical product and process services and is situated within the 56-acre technology research park, currently home to 30 early- and mid-stage technology-driven companies.
It fosters the belief that outsourcing within the industry is on the up as it meets a large, unmet need that demands improved R&D productivity, in the face of declining New Chemical Entity (NCE) introduction and increasing R&D expenses.
Charles River, a company that supplies research models and laboratory animal support services, preclinical services, and clinical services to the biomedical market, has been at the forefront of this upsurge.
The company recently announced the expansion of its California research models production site.
The expansion is expected to double existing production capacity and provide a dedicated barrier room for Preconditioning Services, which include feed and aging studies as well as model characterisation.
Speaking about this latest venture Samuel Pruett, CTP executive director commented: "Charles River's decision to locate one of its research facilities to the CTP is a testament to our resources, facilities and people."
"We want other CROs and life-science companies to know the CTP is an attractive destination to grow their business."
The Chicago Technology Park is a 56-acre research park that fosters the commercialisation of innovative technologies through state-of-the-art facilities and critical support services.
The CTP is administered by the Illinois Medical District in partnership with the University Of Illinois and Rush University Medical Center. The CTP Research Center was one of the first biotechnology incubators in the US and is still one of the largest.